Dr. Yu’s research interests include noncoding RNA pharmacoepigenetics, pharmacogenetics, and cancer therapy. The ultimate goal of our research is to define the mechanistic actions of noncoding RNAs such as microRNAs in the control of cancer cellular processes including drug disposition and tumor progression, and to develop novel noncoding RNA-based therapies. Currently, efforts in his laboratory are directed to the investigation of (a) the roles of noncoding RNAs in the regulation of cytochrome P450 drug-metabolizing enzymes, ATP-binding cassette transporters and oncogenes, and (b) noncoding RNA-based cancer therapeutics.
Dr. Yu also directs the PK/PD Bioanalytical Core Facility at UC Davis that is set up to provide bioanalytical services in support of the clinical and preclinical drug development programs. Investigators who are in need of the services may contact Dr. Yu directly.
Li MM, Wang WP, Wu WJ, Huang M, and Yu AM. Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos. 42(11):1791-1795 (2014).
Bi HC, Pan YZ, Qiu JX, Krausz KW, Li F, Johnson CH, Jiang CT, Gonzalez FJ, and Yu AM. N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291 altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis, 35(10):2264-2272 (2014).
Koh KH, Pan X, Shen HW, Yu AM, Gonzalez FJ, Isoherranen N, Zhang W, and Jeong HY. Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice. J Bio Chem. 289(6):3105-3113 (2014).
Pan YZ, Zhou A, Hu Z, Yu AM. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 41(10): (in press) (2013).
Choi YH, Yu AM. ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development. Curr Pharm Des. 2013 May 13. [Epub ahead of print].
Sze CW, Smith A, Choi YH, Yang XL, Pal U, Yu AM, Li CH. Study of the response regulator Rrp1 reveals its regulatory role on chitobiose utilization and virulence of Borrelia burgdorferi, Infect Immun.81(5):1775-1787 (2013).
Jiang XL, Shen HW, Mager DE, Yu AM. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status, Drug Metab Dispos. 41(5):975-986 (2013).
Bruno AE, Li L, Kalabus JL, Pan YZ, Yu AM, Hu ZH. miRdSNP: a database of disease-associated SNPs and microRNA target sites on 3'UTRs of human genes, BMC Genomics. 13:44 (2012).
Li X, Pan YZ, Seigel GM, Hu Z, Huang M, Yu AM. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells, Biochem Pharmacol. 81(6):783-792 (2011).
Shen HW, Jiang XL, Gonzalez FJ, Yu AM. Humanized transgenic mouse model for drug metabolism and pharmacokinetic research, Curr Drug Metab. 12(10):997-1006 (2011).
Shen HW, Jiang XL, Yu AM. Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice. Drug Metab Dispos. 39(7):1227-1234 (2011).
Pan YZ, Gao WQ, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting, Drug Metab Dispos. 37(10):2112-2117 (2009).
Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates breast cancer resistance protein BCRP/ABCG2 in human cancer cells, Mol Pharmacol. 75(6):1374-1379 (2009).